Search Articles

View query in Help articles search

Search Results (1 to 10 of 29 Results)

Download search results: CSV END BibTex RIS


Peer Review of “Financial Feasibility of Developing Sustained-Release Incrementally Modified Drugs in Thailand’s Pharmaceutical Industry: Mixed Methods Study”

Peer Review of “Financial Feasibility of Developing Sustained-Release Incrementally Modified Drugs in Thailand’s Pharmaceutical Industry: Mixed Methods Study”

Table 3: The values of US $1.46 million and US $18.6 million refer to the research and development costs only, correct? These values do not reflect the total cost of developing IMDs (refer to Table 2). 4. Since most of the numbers come from expert input, how do you ensure that these numbers are valid and accurately reflect real-world situations? It may be helpful to provide more information about the characteristics and qualifications of the key informants to support their credibility. 5.

Parnnaphat Luksameesate

JMIRx Med 2025;6:e78090

Authors’ Response to Peer Reviews of “Financial Feasibility of Developing Sustained-Release Incrementally Modified Drugs in Thailand’s Pharmaceutical Industry: Mixed Methods Study”

Authors’ Response to Peer Reviews of “Financial Feasibility of Developing Sustained-Release Incrementally Modified Drugs in Thailand’s Pharmaceutical Industry: Mixed Methods Study”

Table 3: The values of US $1.46 million and US $18.6 million refer to the research and development costs only, correct? These values do not reflect the total cost of developing IMDs (refer to Table 2). Response: Thank you for your inquiry regarding the values listed in Table 3. To clarify, the figures of US $1.46 million and US $18.6 million indeed represent comprehensive cost assessments.

Manthana Laichapis, Rungpetch Sakulbumrungsil, Khunjira Udomaksorn, Nusaraporn Kessomboon, Osot Nerapusee, Charkkrit Hongthong, Sitanun Poonpolsub

JMIRx Med 2025;6:e77623

Financial Feasibility of Developing Sustained-Release Incrementally Modified Drugs in Thailand’s Pharmaceutical Industry: Mixed Methods Study

Financial Feasibility of Developing Sustained-Release Incrementally Modified Drugs in Thailand’s Pharmaceutical Industry: Mixed Methods Study

In scenario 1, which involves only phase I clinical studies, the R&D process for new sustained-release IMD formulations was estimated to take 7 years, with development costs ranging from US $1.46 to 3.09 million. Approximately 60% of the total costs were allocated to process validation batches, a critical step requiring three consecutive production batches. This phase represents a significant capital investment, with varying costs depending on production complexity.

Manthana Laichapis, Rungpetch Sakulbumrungsil, Khunjira Udomaksorn, Nusaraporn Kessomboon, Osot Nerapusee, Charkkrit Hongthong, Sitanun Poonpolsub

JMIRx Med 2025;6:e65978

Cost Utility Analysis of Internet-Based Cognitive Behavioral Therapy for Major Depressive Disorder: Randomized Controlled Trial

Cost Utility Analysis of Internet-Based Cognitive Behavioral Therapy for Major Depressive Disorder: Randomized Controlled Trial

In total, 3 main categories of costs were identified: intervention costs, health care costs, and societal costs attributed to lost or declined productivity. The health care system perspective accounts for all the costs directly associated with health care services [46], and thus, intervention costs and health care costs are included within this perspective.

Wenjing Zhou, Yan Chen, Herui Wu, Hao Zhao, Yanzhi Li, Guangduoji Shi, Wanxin Wang, Yifeng Liu, Yuhua Liao, Huimin Zhang, Caihong Gao, Jiejing Hao, Gia Han Le, Roger S McIntyre, Xue Han, Ciyong Lu

J Med Internet Res 2025;27:e67567

Effects of a Digital Therapeutic Adjunct to Eating Disorder Treatment on Health Care Service Utilization and Clinical Outcomes: Retrospective Observational Study Using Electronic Health Records

Effects of a Digital Therapeutic Adjunct to Eating Disorder Treatment on Health Care Service Utilization and Clinical Outcomes: Retrospective Observational Study Using Electronic Health Records

Such high utilization contributes to the economic costs of EDs in the United States, estimated recently to be US $64.7 billion (95% CI US $63.5 to US$66.0 billion) [9]. Furthermore, 20 studies were included in a systematic review on the economic burden of anorexia nervosa (AN), bulimia nervosa (BN), and binge eating disorder (BED), finding an association for all 3 conditions with increased health service use, which included emergency, inpatient, and outpatient care [10].

Jorge E Palacios, Kathryn K Erickson-Ridout, Jane Paik Kim, Stuart Buttlaire, Samuel Ridout, Stuart Argue, Jenna Tregarthen

JMIR Ment Health 2024;11:e59145

Wastewater Surveillance Pilot at US Military Installations: Cost Model Analysis

Wastewater Surveillance Pilot at US Military Installations: Cost Model Analysis

In addition, a passive sampling device was prototyped to decrease costs associated with expensive autosampler procurement. We gathered known costs or made estimates of direct costs for all activities required to implement both tier 4 diagnostic testing and WWS protocols. The costs of WWS were based on actual material costs and levels of effort from the WWS pilot study. Costs of tier 4 diagnostic testing were based directly on USAF experience.

Jaleal S Sanjak, Erin M McAuley, Justin Raybern, Richard Pinkham, Jacob Tarnowski, Nicole Miko, Bridgette Rasmussen, Christian J Manalo, Michael Goodson, Blake Stamps, Bryan Necciai, Shanmuga Sozhamannan, Ezekiel J Maier

JMIR Public Health Surveill 2024;10:e54750

Artificial Intelligence as a Potential Catalyst to a More Equitable Cancer Care

Artificial Intelligence as a Potential Catalyst to a More Equitable Cancer Care

Artificial Intelligence (AI) emerges not just as a technological innovation but as a critical instrument with the potential to help overcome critical health challenges, including health care costs, unmet health needs related to the double burden of infectious and noncommunicable diseases, a considerable shortage of trained health professionals, and more importantly, the profound and long-standing inequities in the distribution of the opportunities to health care and well-being [2].

Sebastian Garcia-Saiso, Myrna Marti, Karina Pesce, Silvana Luciani, Oscar Mujica, Anselm Hennis, Marcelo D'Agostino

JMIR Cancer 2024;10:e57276

Connecting Female Entertainment Workers in Cambodia to Health Care Services Using mHealth: Economic Evaluation of Mobile Link

Connecting Female Entertainment Workers in Cambodia to Health Care Services Using mHealth: Economic Evaluation of Mobile Link

Using a top-down or gross approach [10,17], we estimated costs from the perspective of payers and patients. Payer costs, including startup (ie, fixed) costs and other variable costs, were estimated using expenditure data collected during the trial (Table 1).

Anton L V Avanceña, Carinne Brody, Pheak Chhoun, Sovannary Tuot, Siyan Yi

JMIR Form Res 2024;8:e52734

Exploring the Impact of Device Sourcing on Real-World Adherence and Cost Implications of Continuous Glucose Monitoring in Patients With Diabetes: Retrospective Claims Analysis

Exploring the Impact of Device Sourcing on Real-World Adherence and Cost Implications of Continuous Glucose Monitoring in Patients With Diabetes: Retrospective Claims Analysis

No studies have been published examining the impact of the CGM device dispensing source on device adherence and costs, to the authors’ knowledge. To begin closing that knowledge gap, this retrospective analysis of insurance claims data assessed differences in adherence rates and costs among patients with diabetes obtaining CGM supplies through durable medical equipment providers and those using pharmacy services.

Jason C Allaire, Consuela Dennis, Arti Masturzo, Steven Wittlin

JMIR Diabetes 2024;9:e58832